TRVI (Trevi Therapeutics) Interest Expense : $-0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Trevi Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Trevi Therapeutics's interest expense for the three months ended in Dec. 2024 was $ -0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Trevi Therapeutics's Operating Income for the three months ended in Dec. 2024 was $ -12.24 Mil. Trevi Therapeutics's Interest Expense for the three months ended in Dec. 2024 was $ -0.00 Mil. Trevi Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Trevi Therapeutics Interest Expense Historical Data

The historical data trend for Trevi Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trevi Therapeutics Interest Expense Chart

Trevi Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-0.46

-1.20

-1.16

-0.39

Trevi Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Trevi Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

Trevi Therapeutics (NAS:TRVI) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Trevi Therapeutics's Interest Expense for the three months ended in Dec. 2024 was $-0.00 Mil. Its Operating Income for the three months ended in Dec. 2024 was $-12.24 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was $0.75 Mil.

Trevi Therapeutics's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Trevi Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Trevi Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trevi Therapeutics Inc (NAS:TRVI) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

195 Church Street, 16th Floor, New Haven, CT, USA, 06510

Website

https://www.trevitherapeutics.com

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Executives

Thomas Sciascia	10 percent owner, officer: Chief Medical Officer	39 OLD RIDGEBURY RD. SUITE 11, DANBURY CT 06810
Jennifer L Good	director, 10 percent owner, officer: See Remarks	15 GREAT RING ROAD, SANDY HOOK CT 06482
Farrell Simon	officer: Chief Commercial Officer	C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, FLOOR 14, NEW HAVEN CT 06510
David P Meeker	director, 10 percent owner	C/O PENWEST PHARMACEUTICALS CO, 39 OLD RIDGEBURY ROAD SUITE 11, DANBURY CT 06810
Lisa Delfini	officer: Chief Financial Officer	C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, FL. 14, NEW HAVEN CT 06510
David J Clark	officer: Chief Medical Officer	131 HARTWELL AVE, LEXINGTON MA 02421
Tpg Gp A, Llc	10 percent owner	301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Scott D Sandell	10 percent owner
Forest Baskett	10 percent owner
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Ali Behbahani	10 percent owner	5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Carmen Chang	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
New Enterprise Associates 16, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025